Fig. 1 · Structure

Documents & Downloads

Metoprolol tartrate

Cat. No. A11713 CAS 56392-17-7

Beta1 receptor blocker

Metoprolol is a selective β1 receptor blocker used in treatment of several diseases of the cardiovascular system, especially hypertension.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
β1 adrenoceptor  

In Vivo Studies

In male ApoE−/− mice receiving a western diet, Metoprolol treatment was not associated with changes in total plasma cholesterol levels compared with control. In the same model, Metoprolol significantly decreased thoracic aortic atherosclerotic plaque area compared with saline. In male large white pigs subjected to coronary occlusion and reperfusion, the pooled cohort showed lower infarct size relative to the area at risk with Metoprolol than with vehicle, irrespective of ischemia duration. In mice subjected to coronary artery occlusion and reperfusion, Metoprolol administered before reperfusion reduced infarct size normalized to the area at risk compared with vehicle. [1,2,3]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Metoprolol and plasma cholesterol in ApoE−/− mice

Animal study · Male ApoE−/− mice (Taconic Transgenic Models Strain B6.129P2-Apoetm1Unc/N11 Taconic, Denmark), 6 weeks of age [1]

Male ApoE−/− mice receiving a western diet were treated with Metoprolol at 2.5 mg/kg per hour through subcutaneously implanted minipumps. Treatment was not associated with changes in total plasma cholesterol levels compared with control.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
total plasma cholesterol levelstotal plasma cholesterol 11.6 ± 0.4 mmol/L[1]

Conditions shared by the study groups

Route
minipumps were implanted subcutaneously on the back of the mouse
Treatment course
Eleven weeks of metoprolol treatment
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Metoprolol 2.5 mg/kg per hourControl (C, n = 12)Metoprolol treatment was not associated with changes in total plasma cholesterol levels (Control 12.3 ± 0.5 mmol/L versus Metoprolol 11.6 ± 0.4 mmol/L).[1]
Metoprolol 2.5 mg/kg per hour
Model: Male ApoE−/− mice (Taconic Transgenic Models Strain B6.129P2-Apoetm1Unc/N11 Taconic, Denmark), 6 weeks of age
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Metoprolol

The paper names Metoprolol without stating the salt or form; not verified as the tartrate form supplied as A11713. No dose conversion or lot validation.

2. Methods > 2.2. Study I: Dose-Finding > 2.2.1. Experimental Design (S7); 2. Methods > 2.3. Study II: Effects on Atherosclerosis > 2.3.1. Experimental Design (S11, S12, S13); 3. Results > 3.2. Study II: Effects on Atherosclerosis > 3.2.1. Metoprolol Reduced Atherosclerotic Plaque Area (S54); 3. Results > 3.2. Study II: Effects on Atherosclerosis > 3.2.3. Total Cholesterol (S58)

total plasma cholesterol levels: total plasma cholesterol levels; comparator: Control (C, n = 12) — 3. Results > 3.2. Study II: Effects on Atherosclerosis > 3.2.3. Total Cholesterol (S58)

Metoprolol 2.5 mg/kg per hour · 2. Methods > 2.2. Study I: Dose-Finding > 2.2.1. Experimental Design (S7); 2. Methods > 2.3. Study II: Effects on Atherosclerosis > 2.3.1. Experimental Design (S11, S13); 3. Results > 3.2. Study II: Effects on Atherosclerosis > 3.2.1. Metoprolol Reduced Atherosclerotic Plaque Area (S54); 3. Results > 3.2. Study II: Effects on Atherosclerosis > 3.2.3. Total Cholesterol (S58)

Metoprolol and infarct size in pigs

Animal study · 3-month-old male large white pigs weighing 30–35 kg [2]

Male large white pigs subjected to left anterior descending occlusion and reperfusion received intravenous Metoprolol at 0.75 mg/kg or vehicle. In the pooled cohort, infarct size relative to the area at risk was lower with Metoprolol than with vehicle, irrespective of ischemia duration.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Infarct size as % of the AAR (area at risk) at 7-day CMR follow-upIS (% AAR) 72.5 [40–86] % AAR[2]

Conditions shared by the study groups

Route
i.v.
Treatment course
20 min after ischemia onset
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Metoprolol 0.75 mg/kgi.v. vehicle (0.75 ml/kg saline)Pooled cohort: Vehicle 91.7 [70–99] % AAR; Metopr 72.5 [40–86] % AAR; p value < 0.001[2]
Metoprolol 0.75 mg/kg
Model: 3-month-old male large white pigs weighing 30–35 kg
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Metoprolol

The paper names Metoprolol without stating the salt or form; not verified as the tartrate form supplied as A11713. No dose conversion or lot validation.

Methods > Study design (S4, S10, S11, S16, S17, S18); Methods > Pig model of STEMI (ischemia–reperfusion (I/R) protocol) (S29, S30); Methods > Arterial enhanced MDCT protocol and AAR quantification (S38); Methods > CMR protocol and analysis (S45); Fig. 4 legend (S118, S120); Table 2 (T2.h1, T2.h2, T2.r6)

Infarct size as % of the AAR (area at risk) at 7-day CMR follow-up: Infarct size as % of the AAR (area at risk) at 7-day CMR follow-up; comparator: i.v. vehicle (0.75 ml/kg saline) — Fig. 4 legend (S118); Table 2 (T2.h1, T2.h2, T2.r6)

Metoprolol 0.75 mg/kg · Methods > Study design (S10, S11); Table 2 (T2.h1, T2.h2, T2.r6)

Metoprolol and infarct size in mice

Animal study · mice subjected to ischaemia–reperfusion; n = 10 for each condition [3]

Mice subjected to coronary artery occlusion and reperfusion received a single intravenous Metoprolol bolus at 12.5 mg/kg before reperfusion. Infarct size normalized to the area at risk was smaller than in vehicle-treated mice.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
At 24 h post-reperfusion, mice were euthanized, and area at risk (AAR)-normalized IS was calculated.IS (% AAR) 18.0% ± 8.11%[3]

Conditions shared by the study groups

Route
i.v.; through the retro-orbital sinus
Treatment course
a single bolus; 10 min before reperfusion (35 min after ischaemia onset)
Vehicle
0.9% NaCl
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Metoprolol 12.5 mg/kgvehicle-treated micesmaller IS (% AAR) than in vehicle-treated mice (metoprolol, 18.0% ± 8.11%; vehicle, 35.9% ± 10.7%; P = 0.0142)[3]
Metoprolol 12.5 mg/kg
Model: mice subjected to ischaemia–reperfusion; n = 10 for each condition
Methods and source locations

Compound reported in the paper: Metoprolol

The paper names Metoprolol without stating the salt or form; not verified as the tartrate form supplied as A11713. No dose conversion or lot validation.

Results > Metoprolol, but not atenolol or propranolol, limits myocardial infarct size (S4, S5, S7, S9, S10); Figure 1 legend (S60, S63)

At 24 h post-reperfusion, mice were euthanized, and area at risk (AAR)-normalized IS was calculated.: At 24 h post-reperfusion, mice were euthanized, and area at risk (AAR)-normalized IS was calculated.; comparator: vehicle-treated mice — Results > Metoprolol, but not atenolol or propranolol, limits myocardial infarct size (S9, S10)

Metoprolol 12.5 mg/kg · Results > Metoprolol, but not atenolol or propranolol, limits myocardial infarct size (S5, S7, S10)

Metoprolol and aortic plaque area in ApoE−/− mice

Animal study · Male ApoE−/− mice (Taconic Transgenic Models Strain B6.129P2-Apoetm1Unc/N11 Taconic, Denmark), 6 weeks of age [1]

Male ApoE−/− mice receiving a western diet were treated with Metoprolol at 2.5 mg/kg per hour through subcutaneously implanted minipumps. Metoprolol significantly decreased thoracic aortic atherosclerotic plaque area compared with saline.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
plaque area was calculated as the percentage of the total vessel area covered with lesionsReported result Eleven weeks of metoprolol treatment significantly decreased atherosclerotic plaque area in thoracic aorta (P < 0.05, Figures 2(a) and 2(b)).[1]

Conditions shared by the study groups

Route
minipumps were implanted subcutaneously on the back of the mouse
Treatment course
Eleven weeks of metoprolol treatment
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Metoprolol 2.5 mg/kg per hourControl (C, n = 12)Eleven weeks of metoprolol treatment significantly decreased atherosclerotic plaque area in thoracic aorta (P < 0.05, Figures 2(a) and 2(b)).[1]
Metoprolol 2.5 mg/kg per hour
Model: Male ApoE−/− mice (Taconic Transgenic Models Strain B6.129P2-Apoetm1Unc/N11 Taconic, Denmark), 6 weeks of age
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Metoprolol

The paper names Metoprolol without stating the salt or form; not verified as the tartrate form supplied as A11713. No dose conversion or lot validation.

2. Methods > 2.2. Study I: Dose-Finding > 2.2.1. Experimental Design (S7); 2. Methods > 2.3. Study II: Effects on Atherosclerosis > 2.3.1. Experimental Design (S11, S12, S13); 2. Methods > 2.4. Quantification of Atherosclerosis and Immunohistochemistry > 2.4.1. En Face Quantification of Thoracic Aorta (S21, S24); 3. Results > 3.2. Study II: Effects on Atherosclerosis > 3.2.1. Metoprolol Reduced Atherosclerotic Plaque Area (S54)

plaque area was calculated as the percentage of the total vessel area covered with lesions: plaque area was calculated as the percentage of the total vessel area covered with lesions; comparator: Control (C, n = 12) — 2. Methods > 2.4. Quantification of Atherosclerosis and Immunohistochemistry > 2.4.1. En Face Quantification of Thoracic Aorta (S24); 3. Results > 3.2. Study II: Effects on Atherosclerosis > 3.2.1. Metoprolol Reduced Atherosclerotic Plaque Area (S54)

Metoprolol 2.5 mg/kg per hour · 2. Methods > 2.2. Study I: Dose-Finding > 2.2.1. Experimental Design (S7); 2. Methods > 2.3. Study II: Effects on Atherosclerosis > 2.3.1. Experimental Design (S11, S13); 3. Results > 3.2. Study II: Effects on Atherosclerosis > 3.2.1. Metoprolol Reduced Atherosclerotic Plaque Area (S54)

Specifications

Manufacturer Adooq Bioscience
Actions Antagonist
CAS Number 56392-17-7
Applications Beta1 receptor blocker
Formula C34H56N2O12
Molecular Weight 684.81
SMILES
CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.CC(C)NCC(COC1=CC=C(C=C1)CCOC)O.C(C(C(=O)O)O)(C(=O)O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 91 mg/mL (132.88 mM)
Water 91 mg/mL (132.88 mM)
Ethanol 28 mg/mL (40.88 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Ulleryd MA, Bernberg E, Yang LJ, et al. Metoprolol reduces proinflammatory cytokines and atherosclerosis in ApoE-/- mice. Biomed Res Int (2014). PMID: 25105129 DOI: 10.1155/2014/548783 Source material
  2. [2] Lobo-Gonzalez M, Galán-Arriola C, Rossello X, et al. Metoprolol blunts the time-dependent progression of infarct size. Basic Res Cardiol (2020). PMID: 32748088 DOI: 10.1007/s00395-020-0812-4 Source material
  3. [3] Clemente-Moragón A, Gómez M, Villena-Gutiérrez R, et al. Metoprolol exerts a non-class effect against ischaemia-reperfusion injury by abrogating exacerbated inflammation. Eur Heart J (2020). PMID: 33026079 DOI: 10.1093/eurheartj/ehaa733 Source material

Added to your cart

View Cart Checkout
Loading...